Mounjaro is notable for its dual-action mechanism, targeting both GLP-1 and GIP receptors, which enhances its effectiveness in managing blood sugar levels. While Ozempic is often prescribed off ...

Mounjaro is a GLP-1 and GIP receptor agonist. Ozempic acts only on GLP-1. Mounjaro lowers fasting and postprandial glucose concentration, decreases food intake, and reduces body weight in patients ...

The dual action mechanism sets Mounjaro apart from older GLP-1 receptors like Ozempic (semaglutide)—potentially making it more effective for both blood sugar control and weight loss.

the market for GLP-1 drugs is expected to reach $100 billion by 2030. While Mounjaro gives Lilly a first-mover advantage in India, it won't last long, as rival semaglutide (brand name Ozempic ...